While President-elect Donald Trump looks poised to scrap many policies of the Biden administration, one veteran analyst says ...

Lisa Schaffer, with Obesity Canada, joined CTV Morning Live’s Kent Morrison to call for systemic changes on how people view ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

The rise of weight loss drugs is not only changing individual lives, but also reshaping large sections of the economy.

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.

Amid a multi-year, multibillion-dollar spending spree to scale its global manufacturing capacity, Novo Nordisk is laying down ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...

Ozempic promotes weight loss by mimicking the GLP-1 hormone the body naturally produces after eating, so users feel fuller ...

Eli Lilly's Zepbound has outperformed Novo Nordisk's Wegovy in a pivotal clinical trial, marking a significant milestone in ...

Eli Lilly & Co. Inc.'s stock (LLY) rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk's Wegovy in a head-to-head study.